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This article focuses on geographic variability in patient
access to kidney transplantation in the United States.
It examines geographic differences and trends in ac-
cess rates to kidney transplantation, in the component
rates of wait-listing, and of living and deceased donor
transplantation. Using data from Centers for Medi-
care and Medicaid Services and the Organ Procure-
ment and Transplantation Network/Scientific Registry
of Transplant Recipients, we studied 700 000+ patients
under 75, who began chronic dialysis treatment, re-
ceived their first living donor kidney transplant, or
were placed on the waiting list pre-emptively. Rela-
tive rates of wait-listing and transplantation by State
were calculated using Cox regression models, adjusted
for patient demographics. There were geographic dif-
ferences in access to the kidney waiting list and to
a kidney transplant. Adjusted wait-list rates ranged
from 37% lower to 64% higher than the national av-
erage. The living donor rate ranged from 57% lower
to 166% higher, while the deceased donor transplant
rate ranged from 60% lower to 150% higher than the
national average. In general, States with higher wait-
listing rates tended to have lower transplantation rates
and States with lower wait-listing rates had higher
transplant rates. Six States demonstrated both high
wait-listing and deceased donor transplantation rates
while six others, plus D.C. and Puerto Rico, were below
the national average for both parameters.
Key words: Access rates, deceased donor rates, living
donor rates, OPTN, SRTR, wait-listing
Introduction
In the United States, access to the kidney transplant wait-
ing list and to living donor transplantation, among pa-
tients with advanced renal disease, and access to de-
ceased donor transplantation among wait-listed patients
varies markedly by demographic characteristics, etiology
of end-stage renal disease (ESRD), insurance and place
of residence at wait-listing. Prior studies have shown that
the recipients of renal transplants have better survival than
comparable dialysis patients (1–4) and have a better qual-
ity of life (5–9) than do patients on dialysis. In addition,
transplant recipients with longer dialysis exposures have a
higher subsequent rate of graft failure and patient mor-
tality than transplant recipients with shorter dialysis ex-
periences (10–11). Although the final rule governing the
operation of the Organ Procurement and Transplantation
Network (OPTN), published in 1998, requires that patients
with similar diagnoses and disease progression have sim-
ilar access to transplantation (12), a large number of pre-
vious studies have documented the effect of various pa-
tient characteristics on rates of referral (13–19), wait-listing
(17–23), living donor renal transplantation (23–28) and de-
ceased donor renal transplantation (17–19,21,23,26–35),
and have shown that certain patient demographic groups
including minorities, females, older patients, diabetics and
those with only Medicare or Medicaid insurance are rela-
tively less likely to gain access to the waiting list and to
receive a renal transplant (13–35). A few studies have ex-
amined geographic patterns in access to transplantation
(36–38) and identified large variations in opportunity within
the United States. This article examines geographic dif-
ferences and trends in overall rates of access to kidney
transplantation in the component rates of wait-listing, and
of living and deceased donor transplantation that are not
explained by adjustments for patient-specific demographic
variables, insurance or disease state. It also explores inter-
actions between these rates and the opportunity in the
United States for kidney transplantation.
Study Methods
This article summarizes a special study employing data from the Centers
for Medicare and Medicaid Services (CMS) and the Organ Procurement
and Transplantation Network/Scientific Registry of Transplant Recipients
(OPTN/SRTR). The CMS database includes information on all dialysis pa-
tients in the United States. The OPTN/SRTR database includes data on all
wait-listed kidney transplant candidates and recipients in the United States
and is described further in companion articles in this report (39). Both data
sources were supplemented with vital status information from the Social
Security Death Master File (40). Since transplants are rarely performed on
patients older than 75 years, the following wait-listing and transplant data
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discussions are limited to patients younger than 75 at time of entry into the
study.
The study population consisted of 703 202 patients under the age of 75,
who either began chronic dialysis treatment (N = 657 541), received a living
donor kidney transplant without being placed on the OPTN kidney or kidney
pancreas waiting list (N = 5902), or were placed on the OPTN kidney or
kidney-pancreas waiting list for a first transplant prior to initiating chronic
dialysis (pre-emptive wait-listing) (N = 39 849) between 1996 and 2005.
For purposes of this study, States were defined as the fifty States plus
Puerto Rico and the District of Columbia. Patients who had started dialysis,
previously received a transplant, or were placed on the waiting list prior
to 1996 were excluded from this study population. Patients living in a U.S.
territory other than Puerto Rico or with an unknown State of residence were
also excluded. Patients placed on the kidney waiting list prior to the start
of dialysis were considered to have ESRD beginning on the date of wait-
listing. Patients who were added to the waiting list on the same date that
they underwent a living donor kidney transplant were not counted as having
been placed on the waiting list.
This study examined by State and nationally: (1) wait-listing rates among
ESRD patients, (2) living donor kidney transplant rates among ESRD pa-
tients, (3) deceased donor transplant rates among wait-listed patients and (4)
overall (deceased and living donor) transplant rates among ESRD patients.
Patients were followed from the onset of ESRD to the date of wait-listing,
from the onset of ESRD to the date of transplantation, and from the date of
wait-listing to transplantation. The study end-date was December 31, 2005.
Follow-up for wait-listing rates and deceased donor transplant rates was
censored at death, living donor transplant or end of study. Follow-up for
living donor transplant rates was censored at death, deceased donor trans-
plant or end of study. Follow-up for overall transplant rates was censored
at death or end of study.
Multivariable analyses using Cox proportional hazards models, adjusted
for patient demographics that are captured in the CMS and OPTN/SRTR
databases, were used to calculate adjusted rates of wait-listing and trans-
plantation for each State. Adjustments for waiting list rates, living donor
transplant rates and overall transplant rates were patient age, race, ethnic-
ity, gender, cause of ESRD, incidence year (dialysis, living donor transplant,
wait-listing), comorbid conditions and insurance type. Adjustments for anal-
yses of deceased donor transplant rates were patient age at wait-listing,
race, ethnicity, gender, ESRD cause, wait-listing year, comorbid conditions
at wait-listing, insurance type at wait-listing, blood type, panel reactive an-
tibody (PRA) at wait-listing and candidate human leukocyte antigens (HLA).
Results are displayed as the relative rates for each State compared to the
overall or national average reference rate of 1.0. The national average is
taken as the average rate over the States, the District of Columbia and
Puerto Rico.
Table 1: Study population by entry criterion and year, 1996–2005
Entry criterion 1996–2005 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Began dialysis N 657 451 56 855 59 652 62 458 64 758 66 056 67 953 68 476 69 914 70 725 70 604
% 93.50% 94.70% 94.70% 94.40% 94.30% 93.90% 93.90% 93.60% 92.90% 92.20% 91.10%
Pre-emptively wait-listed N 39 849 2720 2826 3251 3338 3650 3698 4030 4656 5299 6381
% 5.70% 4.50% 4.50% 4.90% 4.90% 5.20% 5.10% 5.50% 6.20% 6.90% 8.20%
Received pre-emptive N 5902 489 482 483 587 621 688 674 653 678 547
living donor transp-
lant, never wait-listed
% 0.80% 0.80% 0.80% 0.70% 0.90% 0.90% 1.00% 0.90% 0.90% 0.90% 0.70%
Total N 703 202 60 064 62 960 66 192 68 683 70 327 72 339 73 180 75 223 76 702 77 532
Source: SRTR Analysis, May 2006.
Changes in rates (wait-listing rate, living donor transplant rate and deceased
donor transplant rate) over the 10-year period of the study were estimated
by fitting a Cox model to the national data with year of entry included in
the analysis as a covariate for each of the three rates of interest. This gave
estimates of the overall average annual changes in the national rates of wait-
listing, living donor transplantation and deceased donor transplantation. The
average 5-year changes in rate were taken as the fifth power of the annual
changes. Similarly, separate models were fitted to the data from each State
to obtain State-specific average 5-year increases in the rates.
Trends in Wait-listing and Kidney
Transplanation During the Past Decade
Table 1 shows the study population by entry criterion and
by year of ESRD diagnosis. Between 1996 and 2005, the
number of patients per year starting dialysis as their first
form of ESRD therapy increased progressively from 56 855
to 70 604, and the yearly number of patients pre-emptively
wait-listed more than doubled, from 2720 to 6381. The pat-
tern for patients receiving a living donor kidney transplant
prior to initiation of dialysis (pre-emptive living donor kidney
transplant) was different, though. The number of patients
receiving a pre-emptive living donor transplant without be-
ing wait-listed rose from 489 in 1996 to a peak of 678 in
2004, but that total dropped by 19% to 547 in 2005. The
total percentage of incident ESRD patients who entered
the study prior to initiation of dialysis on the basis of either
pre-emptive wait-listing or pre-emptive living donor trans-
plantation rose steadily over the past decade from 6.5% in
1996 to 8.9% in 2005. Furthermore, during that same in-
terval, an additional 5699 patients, who were preemptively
wait-listed, subsequently went on to receive a pre-emptive
living donor kidney transplant (Table 2).
Table 2 shows that among the 703 202 patients, a total of
159 279 (23%) were placed on the waiting lists for a kid-
ney or kidney-pancreas transplant by December 31, 2005.
Of these wait-listed candidates, 25% (39 849) were wait-
listed prior to initiating dialysis and 61% (96 429) received
a living or deceased donor kidney transplant by December
31, 2005. Of those transplanted, 43% (44 033) received a
living and 57% (58 298) a deceased donor transplant. Ap-
proximately 26% (11 601) of the living donor transplant re-
cipients and 11% (6284) of the deceased donor recipients
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Table 2: Outcomes of study population by entry criterion, 1996–2005
Pre-emptive transplants Not pre-emptive transplants
Entry criterion N Wait-listed All transplants Living donor Deceased donor Living donor Deceased donor
Began dialysis 657 451 119 430 73 172 – – 28 708 44 464
Pre-emptively wait-listed 39 849 39 849 23 257 5699 6284 3724 7550
Received pre-emptive 5902 – 5902 5902 – – –
living donor transplant,
never wait-listed
Total 703 202 159 279 102 331 11 601 6284 32 432 52 014
Source: SRTR Analysis, May 2006.
were transplanted prior to starting dialysis; 13% (5902) re-
ceived a living donor transplant without being wait-listed.
Table 3 shows the number and percentage of patients that
were wait-listed and the percentage of patients that re-
ceived a transplant during the study period by State of
residence. The percentage of ESRD patients per State
that were wait-listed ranged nearly threefold from 13%
to 32%, while the percentage that were wait-listed pre-
emptively varied more than 17-fold from 0.7% to 12%.
Similar patterns were observed among kidney transplant
recipients. The percentage by State of all ESRD patients
receiving a kidney transplant ranged from 8% to 30% and
the percentage of transplants among all ESRD patients
that were pre-emptive ranged from 0.3% to 10%. The
percentage of ESRD patients that received a living donor
transplant ranged from 3% to 20%, while the percentage
of ESRD patients that received a deceased donor trans-
plant ranged from 4% to 14%. Overall, the ratio of liv-
ing donor to deceased donor transplantation was 0.8. The
State ratio ranged from 0.4 to 1.9, with 38 States having
more deceased donor transplants than living donor trans-
plants. Among wait-listed patients, the percentage of pa-
tients receiving a deceased donor transplant ranged from
21% to 67%. As expected, there were strong correlations
between the percentage pre-emptively wait-listed and the
overall percentage wait-listed (r = 0.93, p < 0.0001), be-
tween the percentage pre-emptively wait-listed and the
overall percentage transplanted (r = 0.63, p < 0.0001) and
between the percentage pre-emptively receiving a trans-
plant and the overall percentage transplanted (r = 0.93,
p < 0.0001). Additionally, there was a positive correlation
between living donor and deceased donor transplant rates
(r = 0.66, p < 0.0001).
Access to the Waiting List
The number of patients placed on the kidney waiting list
has increased considerably over the past decade (35). How-
ever, after adjusting for patient age, race, ethnicity, gender,
ESRD cause, year of starting dialysis, comorbid conditions
and insurance type, there are large geographic differences
in access to the kidney transplant waiting list (Figure 1).
These rates ranged from 37% lower than the national av-
erage to 64% higher (RR = 0.63–1.64). The States in the
lowest quartile had relative wait-listing rates that were less
than 0.81 (all statistically significant, p < 0.05), while the
States in the highest quartile had relative rates above 1.23
(all statistically significant, p < 0.05).
Between 1996 and 2005, the average 5-year increase in
the wait-listing rate was 10%. However, this increase was
not uniform across the United States. It is notable that
approximately one-third of the States demonstrated a min-
imal to large 5-year decline in the wait-listing rate (−0.4%
to −33%). In contrast, about one-third of the States real-
ized a 15% or greater 5-year increase in their wait-listing
rate (Figure 2).
Access to a Living Donor Transplant
The number of living donor kidney transplants has in-
creased over the past decade (35), but, as seen in Figure 3,
the opportunity for living donor transplantation varies
widely by State. The living donor transplant rate, after ad-
justing for patient age, race, ethnicity, gender, ESRD cause,
starting year of dialysis, comorbid conditions and insurance
type, ranged from 57% lower to 166% higher than the na-
tional average (RR = 0.43–2.66). The States in the lowest
quartile had living donor transplant rates more than 28%
lower than the national average (all statistically significant,
p < 0.05), while the States in the highest quartile had rela-
tive rates above 129% of the national average (all statisti-
cally significant, p < 0.05).
During 1996–2005, there was an average 5-year increase
in the living donor transplant rate of 12%. Approximately
one-third of the States had an average 5-year decline in the
living donor transplant rate, while during this time period
nearly one-third had more than a 20% increase in the 5-year
rate (Figure 4).
Access to a Deceased Donor Transplant
There are also large and meaningful geographic differences
in deceased donor kidney transplantation rates for wait-
listed patients, ranging from 60% lower to 150% higher
than the national average (RR = 0.40–2.50), after adjust-
ing for patient age, race, ethnicity, gender, ESRD cause,
wait-list year, comorbid conditions, insurance type, blood
type, PRA and HLA antigens (Figure 5). The States in the
lowest quartile had deceased donor transplant rates be-
low 75% of the national average (all statistically significant,
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Table 3: Percent of patients placed on the waiting list and receiving a transplant by State, 1996–2005
Pre- All Pre-emptive Living Deceased Deceased donor
Wait-listed emptive transplants transplants donor donor transplants among
State N (%) WL (%) (%) (%) transplants (%) transplants (%) wait-listed (%)
All 703 202 22.6 5.7 14.6 2.5 6.3 8.3 36.6
AK 737 24.6 4.9 23.2 4.3 13.7 9.5 38.7
AL 13 790 21.9 4.9 11.4 2.1 5.6 5.8 26.5
AR 6679 14.4 2.5 13.1 1.9 5.6 7.5 52.2
AZ 12 107 20.5 4.3 13.8 2.0 7.1 6.6 32.4
CA 81 907 32.4 9.1 13.8 2.2 5.8 8.0 24.7
CO 6394 31.2 9.4 19.5 3.3 8.9 10.6 33.9
CT 6935 19.6 4.6 14.1 3.2 8.1 6.0 30.4
DC 3569 18.1 4.4 7.9 1.3 4.0 3.9 21.3
DE 2179 27.3 8.6 16.6 3.3 7.5 9.1 33.3
FL 38 935 17.4 3.6 13.2 2.1 3.9 9.3 53.7
GA 24 114 15.2 3.2 10.4 1.6 3.6 6.8 44.6
HI 3853 23.6 5.2 10.5 1.5 4.3 6.3 26.5
IA 4906 24.6 7.2 24.5 6.2 12.0 12.5 51.0
ID 1852 22.7 5.7 23.5 4.2 11.8 11.7 51.5
IL 33 006 25.6 7.7 16.3 3.3 6.9 9.4 36.9
IN 13 694 19.1 4.5 15.2 2.7 5.5 9.7 51.0
KS 4957 16.6 4.1 15.6 2.8 5.9 9.7 58.8
KY 9542 15.5 3.2 13.9 2.5 4.8 9.1 58.9
LA 16 286 15.4 2.8 9.7 1.3 3.2 6.5 42.2
MA 11 366 27.8 6.1 19.5 3.7 10.5 9.0 32.4
MD 16 890 27.3 8.1 16.2 3.1 8.0 8.2 30.2
ME 2068 23.0 5.0 20.5 4.3 9.9 10.6 46.0
MI 25 717 24.1 7.0 15.5 3.0 8.2 7.3 30.4
MN 7894 30.7 12.0 30.3 9.8 19.9 10.4 33.9
MO 13 392 19.1 4.4 13.9 2.1 5.2 8.7 45.5
MS 9758 16.8 2.1 8.8 1.1 3.2 5.6 33.5
MT 1343 28.1 7.1 24.7 4.2 12.6 12.1 43.2
NC 23 377 17.8 3.9 10.6 1.7 4.7 5.9 33.0
ND 1082 27.9 10.1 29.8 9.8 18.4 11.4 40.7
NE 3237 21.1 5.4 18.4 3.5 8.4 10.0 47.4
NH 1760 24.4 5.0 22.5 4.4 12.2 10.3 42.1
NJ 22 632 26.9 8.8 14.9 3.0 7.2 7.8 28.9
NM 4482 18.3 4.1 12.0 1.9 5.3 6.6 36.4
NV 4319 26.2 6.6 15.4 2.3 6.3 9.1 34.7
NY 48 380 23.0 5.5 13.4 2.3 6.5 6.8 29.7
OH 29 755 17.9 4.1 15.1 2.7 7.0 8.2 45.7
OK 8396 17.1 3.1 12.2 1.4 3.7 8.5 49.5
OR 5469 17.6 2.9 21.6 3.6 10.6 11.0 62.8
PA 31 168 28.1 8.9 17.8 3.1 5.9 11.9 42.4
PR 9468 12.6 0.7 7.9 0.3 3.3 4.6 36.2
RI 1982 24.0 5.8 21.6 3.4 12.1 9.5 39.7
SC 13 284 16.2 3.3 10.9 1.8 3.3 7.6 46.5
SD 1595 29.3 8.8 23.3 5.2 10.5 12.8 43.6
TN 14 858 18.3 3.0 13.3 1.9 5.3 8.0 43.5
TX 55 691 19.6 2.8 12.6 1.4 4.3 8.3 42.4
UT 2756 19.7 5.4 30.4 7.0 17.2 13.2 66.9
VA 19 192 24.0 6.0 14.4 2.5 7.5 7.0 29.0
VT 908 26.0 8.5 19.7 4.5 9.0 10.7 41.1
WA 9506 24.8 6.5 20.6 3.3 8.7 11.9 48.0
WI 10 416 31.1 10.8 24.7 6.9 11.0 13.7 43.9
WV 4956 18.9 3.7 14.7 2.3 5.5 9.2 48.6
WY 663 26.7 6.3 21.7 4.7 10.6 11.2 41.8
Source: SRTR Analysis, May 2006.
p < 0.05), while the States in the highest quartile had rela-
tive rates above 129% of the national average (all statisti-
cally significant, p < 0.05).
Although the number of deceased donor transplants has
increased by 8% over the past decade, the number
of patients on the waiting list has doubled (35). As a
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∗Adjusted for age, race, ethnicity, sex,
ESRD cause, incidence year, comor-
bid conditions, and insurance type
at incidence; Censored at death, liv-
ing donor transplant, or end of study;
Compared to National average of
1.00; 159,279 of 703,202 were placed
on the waiting list
Source: SRTR Analysis, May 2006.
Figure 1: Relative rate∗ of wait-
listing among ESRD patients by
state, 1996–2005.
consequence of these two dynamics, there has been a
12% average 5-year decrease in the US deceased donor
transplant rate among wait-listed patients from 1996 to
2005. Only 18 states had an increase in the average
5-year deceased donor transplant rate, while 19 states
had more than a 25% average 5-year decrease in this rate
(Figure 6).
The majority of states (N = 31) are served by a single Or-
gan Procurement Organization (OPO). Twelve states do not
have an OPO headquartered within their state and share
an OPO with another state, while nine states have two or
more OPOs. Table 4 shows that compared to states with
Source: SRTR Analysis, May 2006.
Figure 2: Average 5-year change in
wait-listing rate during 1996–2005
by state.
one OPO, wait-list rates are higher both in states that have
no OPOs headquartered in the state and in states with two
or more OPOs (RR = 1.22 and 1.12, respectively, both p <
0.0001). Table 4 also shows that compared to states with
one OPO, states that share an OPO have a 58% higher
rate of living donor kidney transplantation (RR = 1.58,
p < 0.0001), and a 14% higher adjusted rate of deceased
donor kidney transplantation (RR = 1.14, p < 0.0001). In
contrast, states that have two or more OPOs have an 18%
lower living donor adjusted transplant rate (RR = 0.82, p <
0.0001), and an 8% lower adjusted deceased donor kidney
transplant rate (RR = 0.92, p < 0.0001). Similarly, Table 5
shows that states that had more transplant programs had
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*Adjusted for age, race, ethnicity, sex,
ESRD cause, incidence year, comorbid
conditions, and insurance type at inci-
dence; Censored at death, or end of
study; Compared to National average of
1.00; 11,601 of 703,202 received a living
donor transplant
Source: SRTR Analysis, May 2006.
Figure 3: Living donor transplanta-
tion rate∗ among ESRD patients,
1996–2005.
higher wait-list rates and lower deceased donor transplant
rates. Compared to states that have between four and
eight transplant programs, states that have more than nine
programs have higher wait-list rates (RR = 1.07 for 9–15
programs and 1.30 for 15+ programs, both p < 0.0001) and
lower deceased donor transplant rates (RR = 0.78 for 9–
15 programs and 0.76 for 15+ programs, both p < 0.0001).
States with less than three programs have a 7% lower rate
of wait-listing (RR = 0.93, p < 0.0001). There was not a
consistent pattern between the number of transplant pro-
grams and the living donor transplant rate.
Most patients (86.3%) are wait-listed for their initial, pri-
mary listing in the same state as their state of residence
(Table 6). However, the population of kidney transplant
Source: SRTR Analysis, May 2006.
Figure 4: Average 5-year change in
living donor transplant rates during
1996–2005.
recipients that were wait-listed for their initial, primary
listing in a state other than their state of residence had
a higher deceased donor transplant rate than those who
were wait-listed within their state of residence for their
initial, primary listing (RR = 1.04, p < 0.001).
Examining the Relationship Between
Wait-listing Rates and Deceased Donor
Transplantation Rates
Figures 7 and 8 show the states grouped into four cat-
egories based on the adjusted relative wait-listing rates
and deceased donor transplantation rates, conditional upon
wait-listing. The reference relative rate (RR = 1.0) was set
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*Adjusted for age, race, ethnicity, sex,
ESRD cause, wait- list year, comor-
bid conditions, insurance type, blood
type, PRA, and HLA; Censored at
death, living donor transplant or end
of study; Compared to National aver-
age of 1.00; 58, 298 of 159, 279 re-
ceived a deceased donor transplant.
Source: SRTR Analysis, May 2006.
Figure 5: Deceased donor trans-
plantation rate∗ among kidney
waiting list patients by state, 1996–
2005.
at the national average. The four categories were (1) both
wait-listing and deceased donor transplant rates were be-
low the national average (Quadrant I), (2) waitlisting rates
were below and deceased donor transplant rates above
the national average (Quadrant II), (3) wait-listing rates
were above and deceased donor transplant rates below
the national average (Quadrant IV) and (4) both wait-listing
and deceased donor transplant rates were above the na-
tional average (Quadrant III). Only six states (Iowa, Maine,
Pennsylvania, Rhode Island, South Dakota and Wiscon-
sin) had both wait-listing and deceased donor transplant
rates that were above the national average, while six states
Source: SRTR Analysis, May 2006.
Figure 6: Average 5-year change
in deceased donor transplant rate,
1996–2005.
(Arizona, Connecticut, Hawaii, Mississippi, North Carolina
and New Mexico) and the District of Columbia and Puerto
Rico had both wait-listing and deceased donor transplant
rates that were below the national average. There was
a negative correlation (r = −0.65, p < 0.0001) between
wait-listing rates and deceased donor transplant rates after
placement on the waiting list (Figure 8). In general, states
with higher wait-listing rates tended to have lower trans-
plantation rates and states with lower wait-listing rates
showed trends for higher transplant rates. A separate study
of wait-listing and deceased donor transplant rates in the
decades’ two 5-year periods (1996–2000 and 2001–2005)
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Table 4: Relative rate of waiting list and deceased and living donor transplantation by state OPO density, 1996–2005
OPOs residing Waiting p- Living donor p- Deceased donor p-
in the State States Patients list RR1 Value transplant RR1 Value transplant RR2 Value
None3 12 21 125 1.22 < 0.0001 1.58 < 0.0001 1.14 <0.0001
1 OPO 31 347 590 1.00 Ref 1.00 Ref 1.00 Ref
2–4 OPOs4 9 334 487 1.12 < 0.0001 0.82 < 0.0001 0.92 < 0.0001
1Adjusted for patient age, race, ethnicity, gender, ESRD cause, year of starting dialysis and insurance type.
2Adjusted for patient age, race, ethnicity, gender, ESRD cause, waitlisting year, insurance type, blood type, PRA and HLA antigens.
3Shares OPO with another State (AK, DE, ID, ME, MT, ND, NH, RI, SD, VT, WV, WY).
4CA, FL, NC, NY, OH, PA, TN, TX, WI.
Source: SRTR Special Analysis, May 2006.
demonstrated similar correlations (r = −0.691, p < 0.0001
and r = −0.688, p < 0.0001, respectively).
Overall Access to a Transplant
Figure 9 illustrates that the overall kidney transplant (de-
ceased and living combined) rate among all ESRD patients,
after adjusting for patient age, race, ethnicity, gender,
ESRD cause, year of starting dialysis, comorbid conditions
and insurance type, ranged from 52% lower to 107%
higher than the national average (RR = 0.48–2.07). The
states in the lowest quartile had relative transplant rates
below 0.85 (all statistically significant, p < 0.05), while the
states in the highest quartile had relative rates above 1.19
(all statistically significant, p < 0.05).
Figure 10 shows the distribution of adjusted (as described
for each above) relative rates by access metric. These
box plots summarize the state-to-state variability in access
rates. When compared to the national average and despite
adjustments for patient demographics, there are substan-
tial state-to-state differences between the 5th and the 95th
percentiles in all four measures: access to the waiting list,
from 35% less to 50% greater, access to living donor kid-
ney transplantation, from 39% less to 71% greater, access
to deceased donor kidney transplantation, from 48% less
to 99% greater and in overall access to kidney transplan-
tation from 31% less to 64% higher.
Table 5: Relative rate of waiting list and deceased and living donor transplantation by state transplant program density, 1996–2005
Transplant programs Waiting Living donor Deceased donor
residing in the State States Patients list RR1 p-Value transplant RR1 p-Value transplant RR2 p-Value
0–3 programs 28 150 238 0.93 < 0.0001 1.04 0.002 1.01 0.36
4–8 programs3 17 268 980 1.00 Ref 1.00 Ref 1.00 Ref
9–15 programs4 4 115 218 1.07 < 0.0001 1.18 < 0.0001 0.78 <0.0001
15+ programs5 3 168 766 1.30 < 0.0001 0.82 < 0.0001 0.76 <0.0001
1Adjusted for patient age, race, ethnicity, gender, ESRD cause, year of starting dialysis and insurance type.
2Adjusted for patient age, race, ethnicity, gender, ESRD cause, waitlisting year, insurance type, blood type, PRA and HLA antigens.
3 AZ, CO, GA, IA, WI, DC, MN, WA, NC, LA, NJ, OK, VA, IL, MO, FL, TN.
4MA, MI, OH, NY.
5PA, CA, TX.
Source: SRTR Special Analysis, May 2006.
The question could be raised as to whether averages
should be adjusted for variables such as race, ethnicity and
insurance that are recognized barriers to access. Figure 11
shows the relative rates by access measure without these
adjustments. Without adjustment there was little differ-
ence in the observed ranges of variability, and there was
little change in the rankings among the states for each ac-
cess measure (data not shown).
Summary
These results reveal, after adjustment for insurance sta-
tus and for important patient demographic and clinical
variables, both medically and statistically significant ge-
ographic differences in access to the kidney transplant
waiting list, and to living donor and deceased donor kid-
ney transplantation. During the study period, there was a
modest upward trend in pre-emptive wait-listing practices,
but more than 90% of the study population became eligi-
ble for analysis as a consequence of initiation on dialysis.
Twenty-three percent of the 703 202 evaluable patients un-
der age 75 in this study were wait-listed and an additional
5902 underwent a pre-emptive living donor transplant with-
out being added to the deceased donor kidney transplant
waiting list. One quarter of those added to the kidney trans-
plant waiting list were wait-listed prior to initiating dialy-
sis. Almost 15% of the total study population ultimately
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Table 6: Relative rate of deceased donor transplantation by state
residence and waiting list center similarity, 1996–2005
State of residence Deceased
and waiting No. % donor
list the same? Patients Patients transplant RR1 p-Value
Yes 137 386 86.3 1.00 Ref
No 21 893 13.8 1.04 < 0.0001
1Adjusted for patient age, race, ethnicity, gender, ESRD cause,
wait-listing year, insurance type, blood type, PRA and HLA
antigens
Source: SRTR Analysis, May 2006.
received a living donor (6%) or deceased donor (8%) kid-
ney transplant.
Access to kidney transplantation varied markedly by state
for unadjusted observed rates of overall wait-listing, pre-
emptive wait-listing, overall transplantation, pre-emptive
transplantation and living donor and deceased donor trans-
plantation. With adjustment for patient case mix and for
insurance, there remained statistically significant differ-
ences in access by state to the kidney transplant waiting
list, and to either a living or deceased donor kidney trans-
plant.
In general and even with adjustments, states with higher
wait-listing rates had lower transplantation rates and states
with lower wait-listing rates had higher transplant rates
(r = −0.65, p < 0.0001). Six states demonstrated both
wait-listing rates and deceased donor transplant rates
above and six states (plus the District of Columbia and
Puerto Rico) had both wait-listing rates and deceased donor
transplant rates below the national average.
∗Adjusted for age, race, ethnicity,
sex, ESRD cause, incidence year,
comorbid conditions, and insurance
type at incidence;
∗∗Adjusted for age, race, ethnicity,
sex, ESRD cause, wait- list year,
comorbid conditions, insurance type,
blood type, PRA, HLA, and employ-
ment; Censored at death, living donor
transplant or end of study; Compared
to National average of 1.00.
Source: SRTR Analysis, May 2006.
Figure 7: Wait-listing rate∗ among
ESRD patients and deceased
donor transplantation rate∗∗
among waiting list patients by
state, 1996–2005.
This study does not imply that those states with higher
than average wait-listing or transplantation rates are op-
timally meeting the needs of their ESRD population, but
only that they perform in these regards at rates that ex-
ceed the national average. These data do highlight that 20
of the 26 states with higher than average transplantation
rates have lower than average wait-list rates for their ESRD
populations. Conversely, the benefits of wait-listing are di-
minished in 18 of the 24 states with higher wait-listing rates
by the concomitant existence of lower than average rates
for transplantation once wait-listed.
Although this investigation demonstrates the existence of
state-to-state disparities within the United States in access
to kidney transplantation, it does not identify underlying
causes. It may be that much of these differences reflect
variables, not captured in existing databases, that might
reflect regional differences in practice patterns among pri-
mary care physicians, nephrologists and transplant pro-
grams or differing levels of development of health-care in-
frastructure in portions of the country. These disparities
may also reflect different attitudes toward illness, in gen-
eral, or toward renal failure, in particular, among patient
populations that are specific to individual states. A careful
investigation of those states that demonstrate high rates of
wait-listing, coupled with high rates of living and deceased
donor transplantation, may prove valuable in planning in-
terventions aimed at fostering access to transplantation
for the ESRD population.
Potential interventions could be undertaken to improve
both wait-listing and transplantation metrics. To succeed,
such strategies will need to be wide-ranging and include
monitoring of appropriately adjusted referral and wait-
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Source: SRTR Analysis, May 2006.
Figure 8: Correlation of wait-listing rate among ESRD pa-
tients and deceased donor transplantation rates among wait-
ing list patients by state, 1996–2005.
listing rates among dialysis units, referral of eligible deaths
among donor hospitals, OPO performance in converting
referred eligible donors to actual donors, transplant center
acceptance rates for allocated organs and donor service
area discard rates. These disparities warrant the coordina-
tion of efforts and interventions by the dialysis community,
organ procurement and transplant professional communi-
ties, government and patient advocacy groups.
This study documents the degree of geographic disparity
that currently exists within the United States in access to
the kidney transplant waiting list and to living donor and
deceased donor kidney transplantation. These disparities
∗Adjusted for age, race, ethnic-
ity, sex, ESRD cause, incidence
year, comorbid conditions, and in-
surance type at incidence; Cen-
sored at death or end of study; Com-
pared to National average of 1.00;
102,331 of 703,202 received a liv-
ing or deceased donor transplant.
Source: SRTR Analysis, May 2006.
Figure 9: Relative rate∗ of receiv-
ing a kidney transplant among
ESRD patients by state, 1996–
2005.
are not explained by differences in insurance, or by adjust-
ments for important patient demographic variables includ-
ing age, race, gender and cause of ESRD. Posttransplant
patient and graft survival outcomes have been shown to
be negatively correlated with duration of dialysis exposure
(10). Thus, it may be reasonable to extrapolate that these
disparities contribute to morbidity and mortality among af-
fected ESRD patients. In addition, and importantly, the final
rule charges the transplant community with assuring com-
parable opportunities for transplantation for patients with
similar diagnoses and disease progression. It is evident
from these data that this obligation is not being adequately
fulfilled.
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ative access rates∗ compared to the
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